{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:02:15Z","timestamp":1777395735075,"version":"3.51.4"},"reference-count":72,"publisher":"SAGE Publications","issue":"s1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2021,6,22]]},"abstract":"<jats:p>Background: Alzheimer\u2019s disease (AD) causes memory deficit and alterations in other cognitive functions, mainly in adults over 60 years of age. As the diagnosis confirmation is performed by a postmortem neuropathological examination of the brain, this disease can be confused with other types of dementia at early stages. About 860,000 Mexicans are affected by dementia, most of them with insufficient access to adequate comprehensive health care services. Plasma biomarkers could be a rapid option for early diagnosis of the disease. Objective: This study aimed to analyze some plasma biomarkers (amyloid-\u03b2, tau, and lipids) in Mexican AD patients and control subjects with no associated neurodegenerative diseases. Methods: Plasma amyloid-\u03b2 peptides (A\u03b240 and A\u03b242), total and phosphorylated tau protein (T-tau and P-tau), and cholesterol and triglyceride levels were quantified by enzyme-linked immunosorbent assay in AD patients and control subjects. Results: In Mexican AD patients, we found significantly lower levels of A\u03b242 (p\u200a&lt;\u200a0.05) compared to the control group. In contrast, significantly higher levels of P-tau (p\u200a&lt;\u200a0.05) and triglycerides (p\u200a&lt;\u200a0.05) were observed in AD patients compared to controls. Furthermore, a significant correlation was found between the severity of dementia and plasma P-tau levels, A\u03b242\/A\u03b240 and P-tau\/T-tau ratios, and triglycerides concentrations. This correlation increased gradually with cognitive decline. Conclusion: The detection of these plasma biomarkers is an initial step in searching for a timely, less invasive, and cost-efficient diagnosis in Mexicans.<\/jats:p>","DOI":"10.3233\/jad-200912","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T14:11:05Z","timestamp":1623766265000},"page":"S271-S281","source":"Crossref","is-referenced-by-count":7,"title":["Plasma Levels of Amyloid-\u03b2 Peptides and Tau Protein in Mexican Patients with Alzheimer\u2019s Disease"],"prefix":"10.1177","volume":"82","author":[{"given":"Tzayaka","family":"Castillo-Mendieta","sequence":"first","affiliation":[{"name":"Unidad de Investigaci\u00f3n M\u00e9dica en Farmacolog\u00eda, Hospital de Especialidades Bernardo Sep\u00falveda, Centro M\u00e9dico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico"},{"name":"Doctorado en Ciencias Biol\u00f3gicas y de la Salud, Universidad Aut\u00f3noma Metropolitana, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoaly","family":"Arana-Lechuga","sequence":"additional","affiliation":[{"name":"Sleep Disorders Clinic, Universidad Aut\u00f3noma Metropolitana-Iztapalapa, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Campos-Pe\u00f1a","sequence":"additional","affiliation":[{"name":"Laboratorio Experimental de Enfermedades Neurodegenerativas, Instituto Nacional de Neurolog\u00eda y Neurocirug\u00eda Manuel Velasco Su\u00e1rez, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Luisa","family":"Sosa","sequence":"additional","affiliation":[{"name":"Cl\u00ednica de Demencia, Instituto Nacional de Neurolog\u00eda y Neurocirug\u00eda Manuel Velasco Su\u00e1rez, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Orozco-Suarez","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n M\u00e9dica en Enfermedades Neurol\u00f3gicas, Hospital de Especialidades Bernardo Sep\u00falveda, Centro M\u00e9dico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo","family":"Pinto-Almaz\u00e1n","sequence":"additional","affiliation":[{"name":"Laboratorio de Biolog\u00eda Molecular en Enfermedades Metab\u00f3licas y Neurodegenerativas, Unidad de Investigaci\u00f3n, Hospital Regional de Alta Especialidad de Ixtapaluca, Ixtapaluca, State of Mexico, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Segura-Uribe","sequence":"additional","affiliation":[{"name":"Subdirecci\u00f3n de Gesti\u00f3n de la Investigaci\u00f3n, Hospital Infantil de M\u00e9xico Federico G\u00f3mez, Secretar\u00eda de Salud, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo","family":"Javier Rodr\u00edguez-S\u00e1nchez de Tagle","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n M\u00e9dica en Farmacolog\u00eda, Hospital de Especialidades Bernardo Sep\u00falveda, Centro M\u00e9dico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico"},{"name":"Coordinaci\u00f3n de QFBT, Universidad del Valle de M\u00e9xico-Chapultepec, M\u00e9xico City, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Ruiz-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Laboratorio de Neurotoxicolog\u00eda, Instituto Nacional de Neurolog\u00eda y Neurocirug\u00eda Manuel Velasco Su\u00e1rez, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Guerra-Araiza","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n M\u00e9dica en Farmacolog\u00eda, Hospital de Especialidades Bernardo Sep\u00falveda, Centro M\u00e9dico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-200912_ref1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3923\/pjbs.2011.257.272","article-title":"Alzheimer\u2019s disease: Current status of etiopathogenesis and therapeutic strategies","volume":"14","author":"Khairallah","year":"2011","journal-title":"Pakistan J Biol Sci"},{"key":"10.3233\/JAD-200912_ref2","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.pneurobio.2011.11.008","article-title":"The future of Alzheimer\u2019s disease: The next 10 years","volume":"95","author":"Hampel","year":"2011","journal-title":"Prog Neurobiol"},{"issue":"6738 Suppl","key":"10.3233\/JAD-200912_ref3","doi-asserted-by":"crossref","first-page":"A23","DOI":"10.1038\/399a023","article-title":"Translating cell biology into therapeutic advances in Alzheimer\u2019s disease","volume":"399","author":"Selkoe","year":"1999","journal-title":"Nature"},{"key":"10.3233\/JAD-200912_ref4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.31887\/DCNS.2009.11.2\/cqiu","article-title":"Epidemiology of Alzheimer\u2019s disease: Occurrence, determinants, and strategies toward intervention","volume":"11","author":"Qiu","year":"2009","journal-title":"Dialogues Clin Neurosci"},{"key":"10.3233\/JAD-200912_ref6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","article-title":"Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry","volume":"112","author":"Braak","year":"2006","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-200912_ref7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-200912_ref8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1042\/BJ20110369","article-title":"Aggregation of amyloids in a cellular context: Modelling and experiment","volume":"438","author":"Friedman","year":"2011","journal-title":"Biochem J"},{"key":"10.3233\/JAD-200912_ref9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1212\/01.WNL.0000149519.47454.F2","article-title":"Midlife cardiovascular risk factors and risk of dementia in late life","volume":"64","author":"Whitmer","year":"2005","journal-title":"Neurology"},{"key":"10.3233\/JAD-200912_ref10","doi-asserted-by":"crossref","unstructured":"Snipes GJ , Suter U (1997) Cholesterol and myelin. In Cholesterol. Springer, Boston, pp. 173\u2013204.","DOI":"10.1007\/978-1-4615-5901-6_7"},{"issue":"Suppl 2","key":"10.3233\/JAD-200912_ref11","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.3233\/JAD-2011-110599","article-title":"Dyslipidemia and dementia: Current epidemiology, genetic evidence, and mechanisms behind the associations","volume":"30","author":"Reitz","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-200912_ref12","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrn3012","article-title":"Linking lipids to Alzheimer\u2019s disease: Cholesterol and beyond","volume":"12","author":"Di Paolo","year":"2011","journal-title":"Nat Rev Neurosci"},{"key":"10.3233\/JAD-200912_ref13","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3390\/brainsci10060386","article-title":"Cholesterol and Alzheimer\u2019s disease risk: A meta-meta-analysis","volume":"10","author":"S\u00e1iz-Vazquez","year":"2020","journal-title":"Brain Sci"},{"key":"10.3233\/JAD-200912_ref14","doi-asserted-by":"crossref","first-page":"a006312","DOI":"10.1101\/cshperspect.a006312","article-title":"Apolipoprotein E and apolipoprotein E receptors: Normal biology and roles in Alzheimer disease","volume":"2","author":"Holtzman","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.3233\/JAD-200912_ref15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13195-018-0444-1","article-title":"Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: The Fundaci\u00f3 ACE Healthy Brain Initiative (FACEHBI)","volume":"10","author":"De Rojas","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-200912_ref16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"10.3233\/JAD-200912_ref17","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.dadm.2019.05.007","article-title":"Plasma amyloid-beta levels are associated with cerebral amyloid and tau deposition","volume":"11","author":"Risacher","year":"2019","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-200912_ref18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00401-011-0861-8","article-title":"Factors affecting A\u03b2 plasma levels and their utility as biomarkers in ADNI","volume":"122","author":"Toledo","year":"2011","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-200912_ref19","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau-and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-200912_ref20","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/NEN.0b013e31803d3ae4","article-title":"Plasma Abeta levels do not reflect brain Abeta levels","volume":"66","author":"Freeman","year":"2007","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-200912_ref21","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.20730","article-title":"Inverse relation between amyloid imaging load and cerebrospinal fluid Abeta42 in humans","volume":"59","author":"Fagan","year":"2006","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-200912_ref22","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1001\/archneur.60.7.958","article-title":"Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels","volume":"60","author":"Fukumoto","year":"2003","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-200912_ref23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13195-019-0477-0","article-title":"Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer\u2019s disease","volume":"11","author":"Startin","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-200912_ref24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.55782\/ane-2005-1544","article-title":"Plasma levels of alpha-beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer\u2019s disease","volume":"65","author":"Sob\u00f3w","year":"2005","journal-title":"Acta Neurobiol Exp (Wars)"},{"key":"10.3233\/JAD-200912_ref25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0022-510X(96)00143-8","article-title":"Amyloid-beta protein in plasma from patients with sporadic Alzheimer\u2019s disease","volume":"141","author":"Tamaoka","year":"1996","journal-title":"J Neurol Sci"},{"key":"10.3233\/JAD-200912_ref26","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/13506120009146438","article-title":"Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma","volume":"7","author":"Vanderstichele","year":"2000","journal-title":"Amyloid"},{"key":"10.3233\/JAD-200912_ref27","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1212\/01.WNL.0000091890.32140.8F","article-title":"Plasma A[beta]40 and A[beta]42 and Alzheimer\u2019s disease: Relation to age, mortality, and risk","volume":"61","author":"Mayeux","year":"2003","journal-title":"Neurology"},{"key":"10.3233\/JAD-200912_ref28","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0304-3940(01)01754-2","article-title":"Amyloid-beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer\u2019s disease","volume":"304","author":"Mehta","year":"2001","journal-title":"Neurosci Lett"},{"key":"10.3233\/JAD-200912_ref29","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/gps.4053","article-title":"The efficacy of plasma biomarkers in early diagnosis of Alzheimer\u2019s disease","volume":"29","author":"Wang","year":"2014","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.3233\/JAD-200912_ref30","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.dadm.2019.05.001","article-title":"Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer\u2019s disease","volume":"11","author":"Fossati","year":"2019","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-200912_ref31","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1212\/WNL.0000000000003246","article-title":"Plasma tau in Alzheimer\u2019s disease","volume":"87","author":"Mattsson","year":"2016","journal-title":"Neurology"},{"key":"10.3233\/JAD-200912_ref32","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","article-title":"Introduction to the recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Jack","year":"2011","journal-title":"Alzheimers Dement (NY)"},{"key":"10.3233\/JAD-200912_ref33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jalz.2007.08.006","article-title":"Core candidate neurochemical and imaging biomarkers of Alzheimer\u2019s disease","volume":"4","author":"Hampel","year":"2008","journal-title":"Alzheimers Dement (NY)"},{"key":"10.3233\/JAD-200912_ref34","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/archneurol.2008.565","article-title":"A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease","volume":"66","author":"Xia","year":"2009","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-200912_ref35","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1001\/archneurol.2010.189","article-title":"Plasma \u00df-amyloid and cognitive decline","volume":"67","author":"Cosentino","year":"2010","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-200912_ref36","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1474-4422(06)70501-4","article-title":"Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: A prospective case-cohort study","volume":"5","author":"van Oijen","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-200912_ref37","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jalz.2008.10.004","article-title":"Amyloid-beta peptides in human plasma and tissues and their significance for Alzheimer\u2019s disease","volume":"5","author":"Roher","year":"2009","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-200912_ref38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","article-title":"Cerebrospinal fluid and plasma biomarkers in Alzheimer\u2019s disease","volume":"6","author":"Blennow","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-200912_ref39","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3233\/JAD-2011-111418","article-title":"Evaluation of plasma A\u03b2 as predictor of Alzheimer\u2019s disease in older individuals without dementia: A population-based study","volume":"28","author":"Hansson","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-200912_ref40","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1001\/archneur.64.3.354","article-title":"Association of low plasma Abeta42\/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer\u2019s disease","volume":"64","author":"Graff-Radford","year":"2007","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-200912_ref41","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/jama.2010.1995","article-title":"Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline","volume":"305","author":"Yaffe","year":"2011","journal-title":"JAMA"},{"key":"10.3233\/JAD-200912_ref42","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/jnnp.2010.205757","article-title":"Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: A prospective, longitudinal, population-based cohort study","volume":"81","author":"Sepp\u00e4l\u00e4","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-200912_ref43","doi-asserted-by":"crossref","first-page":"100879","DOI":"10.1016\/j.yfrne.2020.100879","article-title":"Sex and gender differences in cognitive and brain reserve: Implications for Alzheimer\u2019s disease in women","volume":"60","author":"Subramaniapillai","year":"2021","journal-title":"Front Neuroendocrinol"},{"key":"10.3233\/JAD-200912_ref44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3233\/JAD-201014","article-title":"Sexual dimorphism in the 3xTg-AD mouse model and its impact on pre-clinical research","volume":"80","author":"Dennison","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-200912_ref45","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13195-020-00712-4","article-title":"APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer\u2019s disease: A systematic review","volume":"12","author":"Emrani","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-200912_ref46","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.dadm.2018.06.004","article-title":"Sex differences in the association between apolipoprotein E \u025b4 allele and Alzheimer\u2019s disease markers","volume":"10","author":"Sundermann","year":"2018","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-200912_ref47","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaneurol.2017.2188","article-title":"Apolipoprotein E genotype and sex risk factors for Alzheimer disease: A meta-analysis","volume":"74","author":"Neu","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-200912_ref48","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/2045-8118-11-26","article-title":"Mechanisms of fluid movement into, through and out of the brain: Evaluation of the evidence","volume":"11","author":"Hladky","year":"2014","journal-title":"Fluids Barriers CNS"},{"key":"10.3233\/JAD-200912_ref49","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.jalz.2016.06.001","article-title":"Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort","volume":"12","author":"Dage","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-200912_ref50","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2217\/17520363.2.4.363","article-title":"Tau as a biomarker of neurodegenerative diseases","volume":"2","author":"Schraen-Maschke","year":"2008","journal-title":"Biomark Med"},{"key":"10.3233\/JAD-200912_ref51","doi-asserted-by":"crossref","first-page":"573324","DOI":"10.3389\/fneur.2020.573324","article-title":"Impact of tau on neurovascular pathology in Alzheimer\u2019s disease","volume":"11","author":"Canepa","year":"2021","journal-title":"Front Neurol"},{"key":"10.3233\/JAD-200912_ref52","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/jamaneurol.2018.4666","article-title":"Assessment of plasma total tau level as a predictive biomarker for dementia and related endophenotypes","volume":"76","author":"Pase","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-200912_ref53","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3233\/JAD-161114","article-title":"Plasma tau association with brain atrophy in mild cognitive impairment and Alzheimer\u2019s disease","volume":"58","author":"Deters","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-200912_ref54","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3233\/JAD-181263","article-title":"Phospho-tau changes in the human CA1 during Alzheimer\u2019s disease progression","volume":"69","author":"Regalado-Reyes","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-200912_ref55","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jamaneurol.2017.3713","article-title":"Associations between Tau, \u03b2-amyloid, and cognition in Parkinson\u2019s disease","volume":"75","author":"Winer","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-200912_ref56","doi-asserted-by":"crossref","first-page":"149","DOI":"10.7326\/0003-4819-137-3-200208060-00006","article-title":"Apolipoprotein E epsilon-4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease","volume":"137","author":"Kivipelto","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.3233\/JAD-200912_ref57","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.neurobiolaging.2003.11.009","article-title":"Cholesterol in neurologic disorders of the elderly: Stroke and Alzheimer\u2019s disease","volume":"25","author":"Reiss","year":"2004","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-200912_ref58","first-page":"213","article-title":"High blood pressure and cardiovascular risk factors in an adult population of Mexico City. Characteristics of the studied population","volume":"27","author":"Yamamoto-Kimura","year":"1996","journal-title":"Arch Med Res"},{"key":"10.3233\/JAD-200912_ref59","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/met.2017.0157","article-title":"Prevalence of metabolic syndrome in Mexico: A systematic review and meta-analysis","volume":"16","author":"Guti\u00e9rrez-Solis","year":"2018","journal-title":"Metab Syndr Relat Disord"},{"key":"10.3233\/JAD-200912_ref60","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.dadm.2017.01.005","article-title":"Pathophysiologic relationship between Alzheimer\u2019s disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis","volume":"7","author":"Santos","year":"2017","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-200912_ref61","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MCO.0000000000000069","article-title":"Role of cholesterol metabolism in the pathogenesis of Alzheimer\u2019s disease","volume":"17","author":"Allinquant","year":"2014","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.3233\/JAD-200912_ref62","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1083\/jcb.200207113","article-title":"Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts","volume":"160","author":"Ehehalt","year":"2003","journal-title":"J Cell Biol"},{"key":"10.3233\/JAD-200912_ref63","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3389\/fnagi.2020.00150","article-title":"APOE alleles and diet in brain aging and Alzheimer\u2019s disease","volume":"12","author":"Yassine","year":"2020","journal-title":"Front Aging Neurosci"},{"key":"10.3233\/JAD-200912_ref64","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.neurobiolaging.2012.10.011","article-title":"APOE and neuroenergetics: An emerging paradigm in Alzheimer\u2019s disease","volume":"34","author":"Wolf","year":"2013","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-200912_ref65","doi-asserted-by":"crossref","first-page":"E6640","DOI":"10.1073\/pnas.1801612115","article-title":"Amyloid clearance defect in ApoE4 astrocytes is reversed by epigenetic correction of endosomal pH","volume":"115","author":"Prasad","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-200912_ref66","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1042\/CS20100094","article-title":"The vascular contribution to Alzheimer\u2019s disease","volume":"119","author":"Altman","year":"2010","journal-title":"Clin Sci (Lond)"},{"key":"10.3233\/JAD-200912_ref67","first-page":"135","article-title":"Heart disease as a risk factor for dementia","volume":"5","author":"Justin","year":"2013","journal-title":"Clin Epidemiol"},{"key":"10.3233\/JAD-200912_ref68","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1212\/WNL.0000000000004749","article-title":"Increased midlife triglycerides predict brain \u03b2-amyloid and tau pathology 20 years later","volume":"90","author":"N\u00e4gga","year":"2018","journal-title":"Neurology"},{"key":"10.3233\/JAD-200912_ref69","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1001\/archneur.61.5.705","article-title":"Relation of plasma lipids to Alzheimer disease and vascular dementia","volume":"61","author":"Reitz","year":"2004","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-200912_ref70","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/aje\/kwh018","article-title":"Relation of education and occupation-based socioeconomic status to incident Alzheimer\u2019s disease","volume":"159","author":"Karp","year":"2004","journal-title":"Am J Epidemiol"},{"key":"10.3233\/JAD-200912_ref71","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ssmph.2018.06.009","article-title":"Socioeconomic status, gender and dementia: The influence of work environment exposures and their interactions with APOE \u025b4","volume":"5","author":"Hasselgren","year":"2018","journal-title":"SSM Popul Health"},{"key":"10.3233\/JAD-200912_ref72","doi-asserted-by":"crossref","first-page":"f7051","DOI":"10.1136\/bmj.f7051","article-title":"Effect of socioeconomic disparities on incidence of dementia among biracial older adults: Prospective study","volume":"347","author":"Yaffe","year":"2013","journal-title":"BMJ"},{"key":"10.3233\/JAD-200912_ref73","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.neuarg.2018.11.001","article-title":"[Social and economic impact of Alzheimer\u2019s disease]","volume":"11","author":"Aranda","year":"2019","journal-title":"Neurol Argentina"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-200912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:06:32Z","timestamp":1777370792000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-200912"}},"subtitle":[],"editor":[{"given":"K.S. Jagannatha","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Gabrielle B.","family":"Britton","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Luisa Lilia","family":"Rocha Arrieta","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Norberto","family":"Garcia-Cairasco","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Alberto","family":"Lazarowski","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Adri\u00e1n","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Antoni Camins","family":"Espuny","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Ricardo B.","family":"Maccioni","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":72,"journal-issue":{"issue":"s1"},"URL":"https:\/\/doi.org\/10.3233\/jad-200912","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,22]]}}}